Showing results (51-60 of 71) with videos related to
Sort By:
Pageof 8
Journal of Crohn'S & Colitis|October 16, 2015
Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and SeverityNiels Teich, Wolfgang Mohl, Bernd Bokemeyer, et al.Plos One|September 20, 2014
Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Claus Niederau, Stefan Mauss, Andreas Schober, et al.Therapeutic Advances in Gastroenterology|November 10, 2022
Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims dataEvi Zhuleku, Beatriz Antolin-Fontes, Andras Borsi, et al.Inflammatory Bowel Diseases|October 27, 2018
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative ColitisBrian G Feagan, Stefan Schreiber, Douglas C Wolf, et al.Journal of Crohn'S & Colitis|March 28, 2025
Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC studyBernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, et al.Inflammatory Bowel Diseases|January 12, 2023
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD StudyBernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, et al.Inflammatory Bowel Diseases|July 31, 2023
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-StudyBernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 21, 2009
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitisAxel U Dignass, Bernd Bokemeyer, Henning Adamek, et al.Journal of Crohn'S & Colitis|March 25, 2025
Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustmentBernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, et al.Wiener Klinische Wochenschrift|October 19, 2007
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel diseaseAlexander Teml, Matthias Schwab, Daan W Hommes, et al.Pageof 8